Alzheimer's breakthroughs stall as federal action lags behind state initiatives
Despite new FDA-approved drugs and a blood test for early detection, many Americans still cannot access Alzheimer’s care because of systemic barriers.
New FDA-approved treatments that target brain amyloid and a cleared blood test for early Alzheimer’s detection represent significant scientific progress, yet many patients remain unable to benefit. The shortage of neurologists and geriatric specialists, combined with varied insurer policies and Medicare’s mandate for trial enrollment, creates a gap between innovation and care. The piece calls for a unified national strategy to expand research investment, streamline regulatory pathways, and make brain-health information widely available.
It also urges insurers to regularly update coverage as evidence evolves, removing geographic and income-based obstacles. Texas’s recent legislation establishing the Dementia Prevention and Research Institute and a $3 billion fund is highlighted as a template for federal leadership.
Why it matters
Alzheimer's affects millions; policy gaps prevent patients from receiving life-changing diagnostics and treatments.
In this story
